ODM-212 / Orion Biotech - LARVOL DELTA

Preclinical evaluation of the novel TEAD inhibitor ODM-212 (ESMO Asia 2025) - P1/2 | "Preclinical data support ODM-212 as a potent and selective pan-TEAD inhibitor with promising pharmacological and safety characteristics. First-in-Human study (NCT06725758) is currently underway to assess its safety, tolerability, pharmacokinetics, and preliminary antitumor activity in patients with advanced solid tumors."

Preclinical • Mesothelioma • Oncology • Solid Tumor • TEAD1 • TEAD2

TEADES PH1/2 STUDY WITH ODM-212: PRELIMINARY RESULTS IN EHE PATIENTS (CTOS 2025) - "TEAD inhibition with ODM-212 has induced durable tumour regression in EHE, demonstrating proof-of-concept for this targeted approach in a TAZ-fusion driven sarcoma. ODM-212 showed encouraging anti-tumour activity and manageable safety, highlighting the potential of targeting the Hippo–YAP/TAZ–TEAD pathway in EHE."

Clinical • Oncology • Sarcoma • Solid Tumor • CAMTA1 • WWTR1

Two-part, first-in-human study on Novel Pan-TEAD inhibitor ODM-212 in subjects with selected advanced solid tumours (TEADES) (ESMO 2025) - P1/2 | "Legal entity responsible for the study Orion Corporation. Funding Orion Corporation."

Clinical • First-in-human • Metastases • P1 data • Mesothelioma • Oncology • Solid Tumor • TEAD1 • WWTR1 • YAP1

Preclinical characterisation of a novel TEAD inhibitor ODM-212 (ESMO 2025) - P1/2 | "Results ODM-212 binds potently and specifically to all TEAD/TEF transcription factors, inhibiting YAP/TAZ-TEAD complex transcriptional activity. Legal entity responsible for the study Orion Corporation. Funding Orion Corporation."

Preclinical • Mesothelioma • Oncology • Solid Tumor • TEAD1 • TEAD2 • YAP1

TEADES: Two-part, First-in-Human Study on ODM-212 in Subjects with Selected Advanced Solid Tumours (clinicaltrials.gov) - P1/2 | N=315 | Recruiting | Sponsor: Orion Corporation, Orion Pharma

Metastases • New P1/2 trial • Oncology • Solid Tumor